Why is Pfizer falling/rising?

As of 31-Oct, Pfizer Ltd. is experiencing a decline in its stock price, currently at 5,215.00, which reflects a decrease of 86.75 or 1.64%. The stock has underperformed its sector by 1.19% today, and while it is higher than the 200-day moving average, it is lower than the 5-day, 20-day, 50-day, and 100-day moving averages. Over the past week, the stock has decreased by 2.26%, contrasting with a 1.25% increase over the past month. Despite a high dividend yield of 3.12% and rising investor participation, as indicated by a 56.08% increase in delivery volume, the overall performance remains weak. The company boasts high management efficiency with a return on equity of 18.22% and a low debt-to-equity ratio, which are positive indicators; however, these factors have not been sufficient to support the stock price in the current market environment.
In the broader market context, Pfizer's recent performance has been notably weaker compared to the benchmark Sensex, which has shown a 0.32% decline over the past week and a 3.65% increase over the past month. Year-to-date, Pfizer's stock has decreased by 0.75%, while the Sensex has gained 7.42%, indicating a significant underperformance relative to the market. The disparity in returns over various periods highlights the challenges Pfizer faces in attracting investor confidence, despite its solid fundamentals and operational performance.